UCT has announced that it received approval from the health authorities of both Kazakhstan and the Russian Federation for its unique CA-62 biomarker cancer testing kit. The CA-62 biomarker test kit uses UCT’s specialized technology to reliably detect the potential presence of cancer at the earliest stages of the disease from just a routine blood draw.
Having initiated the registration process in Kazakhstan and the Russian Federation in 2018, UCT continued to successfully apply the test kit in international clinical studies, in support of the registrations. UCT has successfully tested over 5,000 human blood samples in total since its development program began. That certification process concluded with the Federal Health Care Administration of Russia approving the cancer test kit for use on April 3, 2020. Now, within the Russian Federation UCT’s CA-62 Biomarker Cancer Test Kit can be used on human samples to detect the presence of cancer. It was approved based on the generated clinical data as a medical device called “Set of reagents for in-vitro diagnostic quantitative determination of cancer antigen CA-62 in human blood serum using chemiluminescent analysis CLIA CA-62”. This means that people in the Russian Federation will soon be able to start screening for cancer using the newly approved blood test that offers sensitivity of greater than 90% and specificity of 90%.
UCT worked in parallel with the Healthcare Administration of the Republic of Kazakhstan toward the approval of the cancer test kit as a medical device in Kazakhstan, achieving that goal on October 4, 2019.
“UCT has been working to develop and commercialize this game-changing test for cancer since the company was officially founded in 2018”, UCT co-founder and CEO, Viatcheslav Kondratiev commented, “We are very excited to see this important testing technology available to people in these markets for the first time.”
UCT plans to continue to develop and seek approval for this innovative life-saving technology in other countries around the world.
Contact:
Viatcheslav Kondratiev, CEO
Universal Cancer Technologies (UCT)
800 Petrolia Road, Unit 3,
Toronto, ON M3J 3K4 Canada
Phone: 416-661-7890
Email: [email protected]
About UCT
UCT is an emerging biotechnology company that has developed a sensitive cancer test that can reliably measure the amount of N-glycoprotein CA-62 biomarker in a routine blood draw. The test can detect the majority of epithelial cancer types at all stages of the disease (Stage I through Stage IV), even before a patient may become symptomatic. Because of its non-invasive approach and rapid turnaround time UCT’s CA-62 biomarker test is ideal for screening as well as for monitoring the success of ongoing cancer treatments and identifying relapses in remission patients.
-30-